The Rates of Coexistence Metastases in Patients with Advanced Prostate Cancer in 68Ga-PSMA PET/CT: A Retrospective Analysis

Objective: To determine the rate of metastasis and coexistence metastases in patients with advanced prostate cancer in gallium 68 -prostate specific membrane antigen PET/CT (68Ga-PSMA PET/CT). Material and Method: A total of 234 consecutive patients with advanced prostate cancer who underwent 68Ga-PSMA PET/CT were included in this retrospective study. Data on previous treatments, Gleason score, serum Prostate Specific Antigen (PSA) levels (ng/mL) and 68Ga-PSMA PET/CT findings were recorded. Results: The mean age of the patients was 67.6 ± 8.5 years. Median PSA level was 21.7 (0.2-880) ng/ml. Pelvic (41%) and abdominal (30.3%) lymph nodes were the most commonly involved lymph nodes, while bone metastases were multimetastatic and bone carcinomatosis in 22.2% and 30.6% of patients, respectively. Other common distant organ metastases were lung (7.6%) and liver (7.2%) metastases. Level 1-4 lymph node positivity was noted in 29.4%, 33.3% and 6.8% of patients with liver metastasis, lung metastasis and seminal vesicle invasion, respectively. Concomitant lung metastasis was evident in 41.1% of patients with liver metastasis, while lung or liver metastasis was evident in 13.6% of patients with seminal vesicle invasion. Bone metastasis was evident in all patients with liver and lung metastasis, and in 65.9% of patients with seminal vesicle invasion. Conclusion: The findings of this study showed the value of 68Ga-PSMA PET/CT in detecting coexistence rate of metastases in advanced prostate cancer.

İleri Evre Prostat Kanserli Hastalarda 68Ga-PSMA PET/BT'de Metastazların Birlikte Bulunma Oranları: Bir Retrospektif Analiz

Amaç: İleri evre prostat kanserli hastalarda galyum 68 prostat spesifik membran antijen PET/BT (68Ga-PSMA PET/-BT) de saptanan metastaz ile birlikte bulunan metastazların oranlarını saptamak. Gereç ve Yöntem: Bu retrospektif çalışmaya ilerlemiş prostat kanserli 68Ga-PSMA PET-BT çekimi yapılmış 234 hasta dahil edildi. Hastaların önceki tedavileri, Gleason skorları, serum Prostat Spesifik Antijen (PSA) düzeyleri (ng/ml), 68 Ga-PSMA PET/BT bulguları kaydedildi. Bulgular: Hastaların yaş ortalaması 67.6 ± 8.5 yıl bulundu. Ortanca PSA düzeyi 21.7 (0.2-880) ng/ml idi. Pelvik (%41) ve abdominal (%30.3) lenf nodları en sık görülen lenf nodları metastazları iken, kemik metastazları sırasıyla %22.2 ve %30.6 oranında multimetastatik ve kemik karsinomatozisi şeklindeydi. Diğer yaygın uzak organ metastazları akciğer (%7.6) ve karaciğer (%7.2) metastazları idi. Karaciğer metastazı, akciğer metastazı ve seminal vezikül invazyonu olan hastaların sırasıyla %29.4, %33.3 ve %6.8'inde seviye 1-4 lenf nodu pozitifliği saptandı. Karaciğer metastazı olan hastaların %41.1'inde eş zamanlı akciğer metastazı saptanırken, seminal vezikül invazyonu olan hastaların %13.6'sında akciğer veya karaciğer metastazı saptanmıştır. Karaciğer ve akciğer metastazı olan tüm hastalarda ve seminal vezikül invazyonu olan hastaların %65.9'unda kemik metastazı vardı. Sonuç: Bu çalışmanın bulguları, ilerlemiş prostat kanserinde metastazların birlikte bulunma oranlarının saptanmasında 68Ga-PSMA PET/BT'nin değerini göstermiştir.

___

1. Arnold M, Karim-Kos HE, Coebergh JW, et al. Recent trends in incidence of five common cancers in 26 European countries since 1988: analysis of the European Cancer Observatory. Eur J Cancer 2015; 51: 1164-87.

2. Stephenson AJ, Kattan MW, Eastha m JA, et al. Defining biochemical recurrence of prostate cancer after radical prostatectomy: a proposal for a standardized definition. J Clin Oncol 2006; 24: 3973-8.

3. Ost P, Decaestecker K, Lambert B, et al. Prognostic factors influencing prostate cancer-specific survival in non-castrate patients with metastatic prostate cancer. Prostate 2013; 74: 297-305.

4. Mottet N, Bellmunt J, Bolla M, et al. EAU guidelines on prostate cancer part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 2011; 59: 572-883.

5. Henkenberens C, VON Klot CA, Ross TL, et al. 68Ga-PSMA Ligand PET/CT-based radiotherapy for lymph node relapse of prostate cancer after primary therapy delays initiation of systemic therapy. Anticancer Res 2017; 37: 1273-9.

6. Udovicich C, Perera M, Hofman MS, et al. 68Gaprostate-specific membrane antigen-positron emission tomography/computed tomography in advanced prostate cancer: Current state and future trends. Prostate Int 2017; 5: 125-9.

7. Rauscher I, Maurer T, Fendler WP, Sommer WH, Schwaiger M, Eiber M. (68)Ga-PSMA ligand PET/CT in patients with prostate cancer: How we review and report? Cancer Imaging 2016; 16: 14.

8. Mottet N, Bellmunt J, Bolla M, et al. EAUESTRO-SIOG guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol 2017; 71: 618-29.

9. McGrath S, Christidis D, Perera M, et al. Prostate cancer biomarkers: Are we hitting the mark? Prostate Int 2016; 4: 130-5.

10. Graziani T, Ceci F, Castellucci P, et al. (11)Ccholine PET/CT for restaging prostate cancer. Results from 4,426 scans in a single-centre patient series. Eur J Nuc Med Mol Imaging 2016; 43: 1971- 9.

11. Evangelista L, Briganti A, Fanti S, et al. New clinical indications for 18F/11C-choline, new tracers for positron emission tomography and a promising hybrid device for prostate cancer staging: a systematic review of the literature. Eur Urol 2016; 70: 161-75.

12. Uprimny C, Kroiss AS, Decristoforo C, et al. 68GaPSMA-11 PET/CT in primary staging of prostate cancer: PSA and Gleason score predict the intensity of tracer accumulation in the primary tumour. Eur J Nucl Med Mol Imaging 2017; 44: 941-9.

13. Kitajima K, Murphy RC, Nathan MA, Sugimura K. Update on positron emission tomography for imaging of prostate cancer. Int J Urol 2014; 21: 12-23.

14. Afshar-Oromieh A, Malcher A, Eder M, et al. PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. Eur J Nucl Med Mol Imaging 2013; 40: 486-95.

15. Ceci F, Uprimny C, Nilica B, et al. (68)Ga-PSMA PET/CT for restaging recurrent prostate cancer: which factors are associated with PET/CT detection rate? Eur J Nucl Med Mol Imaging 2015; 42: 1284-94.

16. McCarthy M, Langton T, Kumar D, Campbell A . Comparison of PSMA-HBED and PSMA-I&T as diagnostic agents in prostate carcinoma. Eur J Nuc Med Mol Imaging 2017; 44: 1455-62.

17. Berliner C, Tienken M, Frenzel T, et al . Detection rate of PET/CT in patients with biochemical relapse of prostate cancer using [(68)Ga]PSMA I&T and comparison with published data of [(68)Ga]PSMA HBED-CC. Eur J Nuc Med Mol Imaging 2017; 44: 670-7.

18. Bluemel C, Krebs M, Polat B, et al. 68Ga-PSMAPET/CT in patients with biochemical prostate cancer recurrence and negative 18F-CholinePET/CT. Clin Nuc Med 2016; 41: 515-21.

19. Schmuck S, Nordlohne S, von Klot CA, et al. Comparison of standard and delayed imaging to improve the detection rate of [68Ga]PSMA I&T PET/CT in patients with biochemical recurrence or prostate-specific antigen persistence after primary therapy for prostate cancer. Eur J Nucl Med Mol Imaging 2017; 44: 960-8.

20. Schmuck S, von Klot CA, Henkenberens C, et al. Initial experience with volumetric 68Ga-PSMA I&T PET/CT for assessment of whole-body tumor burden as a quantitative imaging biomarker in patients with prostate cancer. J Nucl Med 2017; 58:1962-8.

21. Afshar-Oromieh, Avtzi E, Giesel FL, et al. The diagnostic value of PET/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging 2015; 42: 197-209.

22. Derlin T, Schmuck S, Juhl C, et al. Imaging characteristics and first experience of [68Ga]THPPSMA, a novel probe for rapid kit-based Ga-68 labeling and PET imaging: comparative analysis with [68Ga]PSMA I&T. Mol Imaging Biol 2018 Jan 17. doi: 10.1007/s11307-018-1160-8.

23. Budäus L, Leyh-Bannurah SR, Salomon G, et al. Initial experience of (68)Ga-PSMA PET/CT imaging in high-risk prostate cancer patients prior to radical prostatectomy. Eur Urol 2016; 69: 393-6.

24. Zacho HD, Nielsen JB, Haberkorn U, Stenholt L, Petersen LJ. 68Ga-PSMA PET/CT for the detection of bone metastases in prostate cancer: a systematic review of the published literature. Clin Physiol Funct Imaging 2017 Oct 29. doi: 10.1111/cpf.12480.

25. Eiber M, Maurer T, Souvatzoglou M, et al. Evaluation of hybrid 68Ga-PSMA ligand PET/CT in 248 patients with biochemical recurrence after radical prostatectomy. J Nucl Med 2015; 56: 668-74.

26. Verburg FA, Pfister D, Heidenreich A, et al. Extent of disease in recurrent prostate cancer determined by [(68)Ga]PSMA-HBED-CC PET/CT in relation to PSA levels, PSA doubling time and Gleason score. Eur J Nucl Med Mol Imaging 2016; 43: 397-403.

27. Bubendorf L, Schopher A, Wagner U, et al. Metastatic patterns of prostate cancer: an autopsy study of 1.589 patients. Hum Pathol 2000; 31: 578-83.

28. Pyka T, Weirich G, Einspieler I, et al. 68GaPSMA-HBED-CC PET for differential diagnosis of suggestive of lung lesions in patients with prostate cancer. J Nucl Med 2016; 57: 367-71.

29. Corfield J, Perera M, Bolton D, Lawrentschuk N. 68Ga-prostate specific membrane antigen (PSMA) positron emission tomography (PET) for primary staging of high-risk prostate cancer: a systematic review. World J Urol 2018 Jan 17. doi: 10.1007/s00345-018-2182-1.

30. Jilg CA, Drendel V, Rischke HC, et al. Diagnostic Accuracy of Ga-68-HBED-CC-PSMA-LigandPET/CT before salvage lymph node dissection for recurrent prostate cancer. Theranostics 2017; 7: 1770-80.

31. Sachpekidis C, Bäumer P, Kopka K, et al. 68GaPSMA PET/CT in the evaluation of bone metastases in prostate cancer. Eur J Nucl Med Mol Imaging 2018 Jan 23. doi: 10.1007/s00259-018-3936-0.

32. Maurer T, Gschwend JE, Rauscher I, et al. Diagnostic efficacy of Gallium-PSMA positron emission tomography compared to conventional imaging in lymph node staging of 130 consecutive patients with intermediate to high risk prostate cancer. J Urol 2016; 195: 1436-43.

33. Maurer T, Weirich G, Schottelius M, et al. Prostate-specific membrane antigen-radio-guided surgery for metastatic lymph nodes in prostate cancer. Eur Urol 2015; 68: 530-4.

34. McCarthy M, Langton T, Kumar D, Campbell A. Comparison of PSMA-HBED and PSMA-I&T as diagnostic agents in prostate carcinoma. Eur J Nucl Med Mol Imaging 2017; 44: 1455-62.
Fırat Tıp Dergisi-Cover
  • ISSN: 1300-9818
  • Başlangıç: 2015
  • Yayıncı: Fırat Üniversitesi Tıp Fakültesi
Sayıdaki Diğer Makaleler

Travmatik Korda Tendinea Rüptürü

Pınar DERVİŞOĞLU, Mustafa KÖSECİK

Ektodermal Displazili Olgularda Klinik ve Radyolojik Bulguların İncelenmesi

Mehmet Sinan DOĞAN, Osman ATAŞ, İzzet YAVUZ, Samet TEKİN

The In-Vitro Impact of Punica Granutum L. (Pomegranate) Juice on Colorectal Cancer Tumors with TP53 and KRAS Mutation

Gülçin TEZCAN, Seçil AK AKSOY, Saliha ŞAHİN, Berrin TUNCA, Gülşah ÇEÇENER

Erzincan İli Genelinde Hastaların Anestezi Uygulamalarından Memnuniyet Durumları ve Etki Eden Faktörler

İlke KÜPELİ

İleri Evre Prostat Kanserli Hastalarda 68Ga-PSMA PET/BT'de Metastazların Birlikte Bulunma Oranları: Bir Retrospektif Analiz

Halil KÖMEK, Tansel Ansal BALCI

Hepatik Ensefalopatili Hastalarımızda Presipitan Faktörlerin Değerlendirilmesi

Kenan ÇADIRCI, Serkan CERRAH

Punica Granutum L. (Nar) Suyunun TP53 ve KRAS Mutasyonu Taşıyan Kolorektal Kanser Tümörlerindeki İn-Vitro Etkisi

Berrin TUNCA, Gülşah ÇEÇENER, Saliha ŞAHİN, Gülçin TEZCAN, Seçil AK AKSOY

Atnalı Böbrek Anomalisi ile Birlikte Böbrek Taşı Tespit Edilen Bir Hastada Laparoskopik Piyelolitotomi: Olgu Sunumu

Emrullah DURMUŞ, Engin ÖZBAY, Remzi SALAR, Halil Ferat ÖNCEL, Talip GÖKTAŞ

The Rates of Coexistence Metastases in Patients with Advanced Prostate Cancer in 68Ga-PSMA PET/CT: A Retrospective Analysis

Halil KÖMEK, Tansel Ansal BALCI

Malign ve Benign Meme Lezyonlarının Ayrımında Kontrastsız Manyetik Rezonans Görüntülemenin Önemi

Ayşegül ALTUNKESER, Serdar ARSLAN, Mehmet Ali ERYILMAZ, Fatih ÖNCÜ, İsmet TOLU, Yaşar ÜNLÜ